Fundraising FoxAugment Ventures — 2021 Investments
3 investments dated 2021 · listed companies and verified rows first · show all
Flume brings transparency to material sourcing and procurement in construction, helping teams plan, compare options, and control costs.
AI & Machine LearningB2B MarketplacesConstruction TechSan Luis Obispo, US
James Fazio(Executive Officer, Director)Eric Adler(Executive Officer, Director, Promoter)
Board seatSonali Vijayavargiya· per SEC Form D
Co-investorsHCAP PartnersTranspose Platform ManagementAccompliceCrosslink CapitalFounder CollectiveOptum Ventures+2 more
Courage Therapeutics is a neuroendocrine biotech developing MC4R agonist drugs for genetic obesity; its lead candidate CTX-B is a weekly injectable targeting melanocortin-4 receptor haploinsufficiency (MC4R HI), a form of early-onset severe obesity with no approved targeted therapy.
BiotechHealthtechLongevityNewton, US
Roger Cone(Co-Founder & CSO)Dan Housman(Co-Founder)Giovanni Ferrara(CEO)Tomi Sawyer(Chief Medicinal Chemist)Sasha Blaug(CBO-CFO)George Grass(Head of Non-Clinical)
Co-investorsArsenal Bridge Venture
RIVET's platform provides workforce management and communication tools for specialty contractors, enabling centralized dispatch of schedules, job assignments, and workforce notifications across field teams.
Construction TechEnterprise SoftwareFuture of WorkSaaSDetroit, US
Louis Gelinas(Executive Officer)inRyan Meitl(Executive Officer, Director)inAndrew(VP of Engineering)PatrickAdamRandy
Co-investorsBrick Mortar VenturesDefy PartnersDetroit Venture PartnersDraper Goren BlockchainMichigan RiseBAM Ventures+2 more
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.